Enteric coated pharmaceutical prolonged release dosage form of a h +, k + -atpase inhibitor, processes for manufacturing it, to improve inhibition of gastric acid secretion, to improve the therapeutic effect in the treatment of gastrointentinal disorders, to receive a prolonged plasma profile of an h +, k + -atpase inhibitor, and, uses of a pharmaceutical composition and h +, k + -atpase inhibitor

摘要

"ENTERED PHARMACEUTICAL PHARMACEUTICAL PROLONGED RELEASE DOSAGE FORM OF AN H ^ + ^, K ^ + ^ -ATPase INHIBITOR, PROCESSES FOR THE MANUFACTURE OF THE SAME, TO IMPROVE THE INHIBITION OF GASTRIC ACID SECRETATION, TO IMPROVE THE TREATMENT OF IT AND TO IMPROVE TREATMENT. OF GASTROINTESTINAL DISORDERS, TO RECEIVE A PLASMA PROFILE PROLONGED FROM AN H ^ + ^, K ^ + ^ -ATPase INHIBITOR, AND, USES OF A PHARMACEUTICAL COMPOSITION AND H ^ + ^, K ^ + ^ -ATPase " An oral enteric pharmaceutical dosage form of prolonged release of an H ^ + ^, K ^ + ^ -ATPase inhibitor, providing a prolonged plasma concentration of an H ^ + ^, K ^ + ^ -ATPase inhibitor. The extended plasma profile is obtained by a pharmaceutical composition comprising a core material of a hydrophilic or hydrophobic matrix and the H ^ + ^, K ^ + ^ -ATPase inhibitor and, optionally, pharmaceutically acceptable excipients. The dosage form can be administered once daily.